RaQualia looks to progress lead EP4 inhibitor on back of Aratana deal
This article was originally published in Scrip
Executive Summary
Pfizer Japan spin-out RaQualia Pharma expects a new active pharmaceutical ingredient (API) development agreement with the private US firm Aratana Therapeutics to help progress the development of one of its most advanced pipeline candidates.